FCYC+Conventional treatment
ApprovedSmall molecule
FCYC+Conventional treatment is one of 37 small molecule programs targeting Intracerebral Hemorrhage. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
88 competitors in Intracerebral Hemorrhage
#DrugCompanyPhaseTrials
1Colcrys
Alnylam PharmaceuticalsPhase 3
Activase
RochePhase 3
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Statin
Bristol-Myers SquibbPhase 3
Olumiant
Eli LillyPhase 2
Crestor
AstraZenecaPhase 2
Desferal
Alnylam PharmaceuticalsPhase 2
Tecfidera
BiogenPhase 2
Actos
TakedaPhase 2
Minocycline /d
UUniversity of Florida
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for FCYC+Conventional treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details